S. Beal, Conditioning on Certain Random Events Associated with Statistical Variability in PK/PD, Journal of Pharmacokinetics and Pharmacodynamics, vol.92, issue.46, pp.213-243, 2005.
DOI : 10.1007/s10928-005-0090-7

Y. Benjamini and Y. Hochberg, Controlling the false discovery rate: a practical and powerful approach to multiple testing, J Roy Stat Soc B Met, vol.57, pp.289-300, 1995.

M. Bodor, E. Kelly, and R. Ho, Characterization of the humanMDR1 gene, The AAPS Journal, vol.7, issue.1, pp.1-5, 2005.
DOI : 10.1208/aapsj070101

H. Bozdogan, Model selection and Akaike's Information Criterion (AIC): The general theory and its analytical extensions, Psychometrika, vol.10, issue.2, pp.345-370, 1987.
DOI : 10.1007/BF02294361

K. Brendel, M. Legrand, A. Taburet, G. Baron, C. Goujard et al., Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy, Fundamental and Clinical Pharmacology, vol.40, issue.3, pp.373-83, 2005.
DOI : 10.1097/00002030-200305230-00007

K. Burnham and D. Anderson, Model Selection and Multimodel. A practical Information-Theoric approach, 2002.

E. Comets and F. Mentré, EVALUATION OF TESTS BASED ON INDIVIDUAL VERSUS POPULATION MODELING TO COMPARE DISSOLUTION CURVES, Journal of Biopharmaceutical Statistics, vol.11, issue.3, pp.107-123, 2001.
DOI : 10.1081/BIP-100107652

C. Csajka, C. Marzolini, K. Fattinger, L. Decosterd, A. Telenti et al., Population Pharmacokinetics of Indinavir in Patients Infected with Human Immunodeficiency Virus, Antimicrobial Agents and Chemotherapy, vol.48, issue.9, pp.3226-3258, 2004.
DOI : 10.1128/AAC.48.9.3226-3232.2004

J. Fellay, C. Marzolini, E. Meaden, D. Back, T. Buclin et al., Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study, The Lancet, vol.359, issue.9300, pp.30-36, 2002.
DOI : 10.1016/S0140-6736(02)07276-8

J. Gabrielsson and D. Weiner, Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications, 1999.

P. Girard and F. Mentré, A comparison of estimation methods in nonlinear mixed effects models using a blind analysis, PAGE, vol.14, 2005.

C. Goujard, M. Legrand, X. Panhard, B. Diquet, X. Duval et al., High Variability of Indinavir and Nelfinavir Pharmacokinetics in HIV-Infected Patients with a Sustained Virological Response on Highly Active Antiretroviral Therapy, Clinical Pharmacokinetics, vol.30, issue.12, pp.1267-78, 2005.
DOI : 10.2165/00003088-200544120-00005

A. Henningsson, S. Marsh, W. Loos, M. Karlsson, A. Garsa et al., Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 Polymorphisms with the Pharmacokinetics of Paclitaxel, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel, pp.8097-8104, 2005.
DOI : 10.1158/1078-0432.CCR-05-1152

F. Innocentia, W. Liua, P. Chenb, A. Desaia, S. Dasb et al., Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes, Pharmacogenetics and Genomics, vol.15, issue.5, pp.295-301, 2005.
DOI : 10.1097/01213011-200505000-00004

B. Kappelhoff, A. Huitema, S. Sankatsing, P. Meenhorst, V. Gorp et al., Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients, British Journal of Clinical Pharmacology, vol.24, issue.3, pp.276-86, 2005.
DOI : 10.1067/mcp.2002.121424

T. Kerbusch, U. Milligan, P. Karlsson, and M. , Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability, British Journal of Clinical Pharmacology, vol.56, issue.6, pp.639-652, 2003.
DOI : 10.1046/j.1365-2125.2003.01967.x

J. Licinio and M. Wong, Pharmacogenomics The search for individualized therapy, 2002.

D. Machin, M. Campbell, P. Fayers, and A. Pinol, Sample size tables for clinical studies, 1997.
DOI : 10.1002/9781444300710

K. Mamiya, A. Hadama, E. Yukawa, I. Ieiri, K. Otsubo et al., CYP2C19 polymorphism effect on phenobarbitone, European Journal of Clinical Pharmacology, vol.55, issue.11-12, pp.821-825, 2000.
DOI : 10.1007/s002280050703

C. Marzolini, E. Paus, T. Buclin, and R. Kim, Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance, Clinical Pharmacology & Therapeutics, vol.75, issue.1, pp.13-33, 2003.
DOI : 10.1016/j.clpt.2003.09.012

T. Meerum, M. Malingre, J. Beijnen, B. Ten, W. Huinink et al., Co-administration of cyclosporine A enables oral therapy with paclitaxel, Clin Cancer Res, vol.5, pp.3379-84, 1999.

F. Mentré, X. Duval, E. Rey, G. Peytavin, S. Auleley et al., Prospective trial to evaluate how therapeutic drug monitoring of protease inhibitors increases virologic success and tolerance of HAART (COPHAR 2 - ANRS 111 trial, 12th Conference on Retroviruses and Opportunistic Infections, 2005.

D. Min, V. Ellingrod, S. Marsh, and H. Mcleod, CYP3A5 Polymorphism and the Ethnic Differences in Cyclosporine Pharmacokinetics in Healthy Subjects 1, Therapeutic Drug Monitoring, vol.26, issue.5, pp.524-528, 2004.
DOI : 10.1097/00007691-200410000-00010

X. Panhard and F. Mentré, Evaluation by simulation of tests based on non-linear mixed-effects models in pharmacokinetic interaction and bioequivalence cross-over trials, Statistics in Medicine, vol.83, issue.10, 2005.
DOI : 10.1002/sim.2047

A. Raftery, Bayesian Model Selection in Social Research (with discussion), Sociol Methodol, pp.111-195, 1995.

S. Retout, E. Comets, A. Samson, and F. Mentre, Design in nonlinear mixed effects models: Optimization using the Fedorov???Wynn algorithm and power of the Wald test for binary covariates, Statistics in Medicine, vol.39, issue.28, 2007.
DOI : 10.1002/sim.2910
URL : https://hal.archives-ouvertes.fr/hal-00263513

S. Retout and F. Mentre, Optimization of Individual and Population Designs Using Splus, Journal of Pharmacokinetics and Pharmacodynamics, vol.30, issue.6, pp.417-460, 2003.
DOI : 10.1023/B:JOPA.0000013000.59346.9a

T. Sakaeda, T. Nakamura, and K. Okumura, MDR1 Genotype-Related Pharmacokinetics and Pharmacodynamics, Biological & Pharmaceutical Bulletin, vol.25, issue.11, pp.1391-1400, 2002.
DOI : 10.1248/bpb.25.1391

A. Samson, M. Lavielle, and F. Mentré, The SAEM algorithm for group comparison test in longitudinal data analysis based in nonlinear mixed-effects model, 2007.

G. Schwartz, Estimating the Dimension of a Model, The Annals of Statistics, vol.6, issue.2, pp.461-464, 1978.
DOI : 10.1214/aos/1176344136

L. Sheiner and S. Beal, NONMEM Version 5.1. San Francisco University of California, 1998.